The purpose of this study was to determine whether decreased FcγRIII expression on the PMN of extremely low birth weight infants (ELBW) is due to decreased receptor synthesis or increased receptor shedding from the PMN surface. 42 ELBW, 12 larger infants and 14 adults were enrolled. Plasma and total cellular FcγRIII were measured by ELISA, and PMN FcγRIII expression was measured by flow cytometry. ELBW PMN plasma membrane expression of FcγRIII as measured by log mean channel fluorescence (5.00 ± 1.98 vs. 10.68 ± 1.61, p < 0.050) and plasma FcγRIII levels were both lower (7.5 ± 6.1 vs. 82.4 ± 64.8 nM, p < 0.05) than in adult controls. In follow-up studies, 14 ELBW (age = 29 ± 14 days, range = 14-56 days) increased PMN expression of FcγRIII (p < 0.001) but not plasma FcγRIII. ELBW had lower total PMN-associated FcγRIII than adults (2.3 ± 0.9 vs. 6.8 ± 2.2 ng/l06 PMN, p = 0.006). ELBW’s PMN produce less FcγRIII than adults’ PMN, and expression of this receptor is developmentally regulated.

Keywords:
ELISA, FcγRIII, PMN, Premature infants, Flow cytometry
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.